v
Search
Advanced Search

Publications > Journals > Journal of Exploratory Research in Pharmacology > Article Full Text

  • OPEN ACCESS

Bioequivalence Studies of Two Brands of Linagliptin Tablets in Healthy Adults Under Fed and Fasted Conditions

  • Xin Li1,#,* ,
  • Fang Yuan1,#,
  • Bing Xu1,
  • Ke Yao2,
  • Gui-Ying Xiao1,3,
  • Yuan Li1,
  • Ping Zhang1 and
  • Sheng-Qing Tu1
 Author information
Journal of Exploratory Research in Pharmacology 2022

doi: 10.14218/JERP.2022.00035

Abstract

Background and objectives

This study aimed to summarize the clinical pharmacokinetics and bioequivalence of generic and branded linagliptin tablets during fasting and fed conditions, and the influence of food on the pharmacokinetics (PK) of linagliptin tablets was also explored in healthy Chinese subjects.

Methods

An open-label, randomized, single-center, two-period, and single-dose crossover bioequivalence study was performed in this research. Healthy subjects in fasting (n = 32) and fed (n = 32) conditions received 5 mg of generic (test) linagliptin or a commercial (reference) capsule, respectively. Blood sample collection was conducted at the baseline and post-dose. Plasma concentrations of linagliptin were detected by an HPLC-MS/MS method. A non-compartmental method was performed to analyze pharmacokinetic parameters, and safety was monitored.

Results

A total of 64 subjects completed the study, 32 for the fasting and 31 for the fed study. The major PK parameters of linagliptin, including Cmax and AUC0–72, were similar between the preparations under fasting and fed conditions. Under fasting conditions, the 90% confidence intervals (CI) of the test/reference ratios (T/R) of Cmax and AUC0–72 were 95.9∼110.9% and 96.8∼101.9%, respectively. Under fed conditions, the 90% CI of T/R of Cmax and AUC0–72 were 98.2∼103.4% and 97.7∼103.5%, respectively. None of the volunteers had a severe adverse event.

Conclusions

Generic linagliptin tablet is bioequivalent to the reference drug under both fasting and feeding conditions. Food delays the absorption of linagliptin. Chinese subjects taking a single dose of linagliptin of 5 mg have good tolerance to the drug.

Keywords

Linagliptin, DPP-4 inhibitor, Bioequivalence, Pharmacokinetics

Introduction

Diabetes mellitus (DM) is a metabolic disorder characterized by an abnormal glucose and lipid metabolism causing persistent hyperglycemia.1,2 About 95 percent of diabetes cases belong to type 2 diabetes mellitus (DM2), characterized by insulin resistance (IR).3 Diabetes, an epidemic connected with the combination of social, behavioral, fetal, and genetic factors, is one of the greatest health problems of the 21st century.4 Recent statistics from the International Diabetes Federation show that 425 million adults worldwide had diabetes in 2017. A total of 629 million people are expected to suffer from diabetes by 2045.5 There have been many advances in treating DM2; however, reaching optimal glycemic goals remains a question.

The incretins such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) secreted from enteroendocrine K and L cells could stimulate pancreatic beta cells to secrete insulin,6,7 both incretins are rapidly degraded by the enzyme dipeptidyl peptidase-4 (DPP4). Early studies have shown DPP4 revolved in the pathogenesis of IR,8 hyperglycemia,9 dyslipidemia,10,11 obesity,12,13 oxidative stress,14 inflammation,1517 and malignant tumors.18 Inhibition of DPP4 enzymes and prolonged endogenous GLP-1 and GIP concentrations in the blood has become a new target for managing DM2.19 A clinical study20 showed that linagliptin was involved in significantly fewer cardiovascular events. Like a placebo, linagliptin did not affect the risk for the secondary kidney outcome in participants with DM2 and CKD and/or CV disease.21 Up until now, over ten DPP4 inhibitory drugs classified as gliptins have been approved by the FDA:22 sitagliptin, linagliptin, vildagliptin, teneligliptin, saxagliptin, omarigliptin, gemigliptin, alogliptin, anagliptin, trelagliptin, evogliptin, and gosogliptin.23 Unlike other DPP4 inhibitors, linagliptin is almost wholly bound (99%) to plasma proteins (mostly the DPP-4 enzyme) in the early animal study.24 Human studies have indicated that hepatobiliary clearance is the predominant mechanism of clearance of linagliptin, which is perhaps connected with its extensive binding characteristics.24,25 Such characteristics suggested that kidney excretion is a non-primary way of eliminating linagliptin. Linagliptin administration does not require dosage adjustment in clinic patients with declining renal function.26 Pharmacokinetics (PK) and pharmacodynamics of linagliptin are unique in that they are described by target-mediated non-linear PK and a comprehensive safety window.27,28 Another, linagliptin significantly improved glycemic control in type 2 diabetes inadequately controlled on basal insulin.29 At present, a generic linagliptin tablet is being developed by Chengdu Brilliant Pharmaceutical Co., Ltd. According to China National Medical Products Administration, a bioequivalence study was required to support registration.

Oral drug absorption is an intricate process and can be influenced by numerous factors. Food plays a primary role in the bioavailability of drugs orally administered. By affecting the solubility and intestinal permeability,30 food may alter the absorption, metabolism, excretion, and other processes of the drug in the gastrointestinal tract via numerous food-drug interactions.31 Ahmad Y Abuhelwa’s study32 has demonstrated that drug dissolution or solubility, drug stability, drug release, and intestinal permeability all was significantly affected by food intake. Following a meal, gastric emptying rate, dissolution, GI luminal metabolism, pH, and bile flow were reconfigured, contributing to delayed drug absorption.33 Christina S Won’s study34 about mechanisms underlying food-drug interactions also manifested that fruit juices, teas, and other commonly consumed could inhibit the activity of intestinal cytochrome P450 or phase II conjugation enzymes, decrease the expression of uptake and efflux transport proteins, which caused the changed in bioavailability of drugs.

This study aimed to assess the bioequivalence between generic linagliptin tablets and branded preparation under fasting and fed conditions. In addition, the food effect on PK of linagliptin tablet was also evaluated in healthy Chinese volunteers.

Materials and methods

Subjects

Healthy Chinese volunteers aged over 18 years with a body mass index of 19–26 kg/m2 were qualified for inclusion. All volunteers were evaluated during screening visits, including physical examinations, vital signs, electrocardiogram (12-lead), laboratory tests (coagulation function, hematology, blood chemistry, urinalysis), serologic tests (HBV surface antigen, antibodies including HCV, HIV, and syphilis) and a history of medication. Participants agreed to use effective contraception from two weeks before screening through 3 months after the end of the trial. Primary exclusion criteria included (a) clinically meaningful abnormality in vital signs, electrocardiogram, physical examinations, or laboratory results according to the physician’s judgment; (b) the presence or history of endocrine, cardiovascular, metabolic, psychiatric, and neurological diseases; (c) allergy to any drugs or food; (d) Over 400 mL of blood lost; (e) surgery operated within four weeks before entry into the study or scheduled during this study; (f) pregnancy or lactation ; (g) consume plenty of tea, coffee, or caffeinated beverages; (h) heavy smokers ≥5 cigarettes per day or alcoholics weekly alcohol ≥14 units; (i) Substance abuse and positive substance abuse screening tests including morphine, 3,4-methylenedioxyamphetamine, ketamine, methamphetamine, tetrahydrocannabinol, and cocaine.

Study drugs and reagents

The generic (or test) preparation, a linagliptin tablet, 5 mg (batch no: 200401, Exp: April 2023), was provided by Chengdu Brilliant Pharmaceutical Co., Ltd., and the branded (or reference) preparation, linagliptin tablet 5 mg (batch no: AA6924A, Exp: January 2022) was obtained from Boehringer Ingelheim International GmbH, Germany.

Study design

This randomized, open-label, single-center, single-dose, and two-sequence crossover study to evaluate the bioequivalence of test and reference linagliptin under fed and fasting conditions was conducted in healthy volunteers (Fig. 1). This clinical trial strictly adheres to the ethical guidelines of The Declaration of Helsinki on human medical research. The protocol and informed consent of the clinical trial were approved by the Ethics Committee of the Third Hospital of Changsha (Approval No. 2020EC-007). This study was registered at www.chinadrugtrials.org.cn (registration number: CTR20201729).

The flowchart of the clinical trial design in fasting cohort (a) and fed cohort (b).
Fig. 1  The flowchart of the clinical trial design in fasting cohort (a) and fed cohort (b).

Sixty-four volunteers who satisfied all the criteria for inclusion were included in this study, and 32 participants were assigned to the fasting and fed groups, respectively. Subjects were randomly divided into two sequence groups (T-R, R-T). Statistical Analysis System (SAS) 9.4 software randomly assigned participants into two groups. The washout period was 36 days between treatment periods. After an overnight fast of at least 10 hours, subjects in the fasting cohort received 240 mL of water after oral administration of tablets of the test or reference linagliptin. A restriction was placed on water consumption one hour before and after administration. The subjects in the fed cohort ingested a standard high-fat meal (800–1,000 kcal) 30 minutes prior to the administration. All subjects were checked in real-time to confirm the drug was entirely swallowed.

Blood Sample

Fasting blood samples (4 mL) were obtained predose and at 15, 30, 45, 60, 75, 90, and 105 min and 2, 2.25, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48, and 72 h after dosing. Fed blood samples (4 mL) were obtained predose and at 15, 30, 45, 60, 80, and 100 min and 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, and 72 h after dosing. Immediately after collecting blood samples, plasma was centrifuged at 1,700 g (2–8°C, 10 minutes) and stored at −60°C until further analysis.

Analytical Method and Method validation

A liquid-liquid extraction method was applied to extract linagliptin from plasma. A validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was used to analyze plasma levels of linagliptin. Briefly, linagliptin from the plasma was extracted using a liquid-liquid extraction technique and separated on a 2.0×50 mm, 5 µm CAPCELL PAK C18 column (Shiseido Co Ltd). Water containing salt solution: formic acid LC: ultrapure water (5:1:1,000, V/V/V) (solvent A) and acetonitrile (solvent B) made up the mobile phase. With a flow rate of 0.400 mL/min, elution was performed as follows: 0.01–0.5 min, linearly increase B from 20% to 90%; 0.5–1.5 min, isocratic A: B = 10:90; 1.51–2.5 min, the system was switched back to the initial proportion (20% B), the column was equilibrated for 3 min with a column heater at 40 °C. An electrospray mass spectrometer operated in multiple reaction monitoring modes with positive ionization. The optimal parameters for the tandem mass spectrometer were as follows: curtain gas, ion spray voltage, temperature, ion source gas 1, and ion source gas 2 were instrumented in the following settings: 30 psi, 5,500 V, 550°C, 50 psi, and 60 psi, respectively. Potentials for declustering, entrance, and collision cell exits were set to 90 V, 12 V, and 11V for linagliptin, 110 V, 8 V, and 8V for linagliptin-13C-d3, respectively. The collision energy was set at 35 eV. In using electrospray ionization to monitor multiple reactions, the transition m/z was 473.4 to 420.4 for linagliptin and 477.4 to 420.5 for linagliptin-13C-d3. Software Analyst 1.6.3 was used to analyze the mass spectrum data (AB SCIEX, Foster City, California). The linear range, intra-day precision, inter-day precision and accuracy were 0.20 to 12.0 ng/mL, 2.9% to 8.1%, 2.5% to 6.9%, and within 97.6% to 101.0%, respectively. Seven calibration plasma samples for linagliptin were prepared by spiking standard solutions (at the concentrations of 4.0, 8.0, 20.0, 60.0, 120.0, 200.0, and 240.0 ng/mL, respectively) into drug-free blank plasma with appropriate volume ratio. The concentrations of quality control (QC) samples were 4.0, 12.0, 80.0, 160.0 ng/mL. The method was validated in light of the guideline on Bioanalytical Method Validation from the EMA,15 including specificity, linearity, the lower limit of quantification, accuracy, precision, matrix effect, extraction recovery, stability, and the QC during the subject sample analysis.

Pharmacokinetic Parameters and Statistical Analyses

Major PK parameters, including maximum plasma drug concentration (Cmax), time to reach maximum plasma concentration (Tmax), and area under the plasma concentration-time curve (AUC) from zero to time 72 h (AUC0–72), were calculated based on plasma concentration-time data. PK parameters were analyzed with WinNonlin 8.0 (Pharsight Corporation, Sunnyvale, California) using noncompartmental models. A linear mixed ANOVA model was used to analyze the log-transformed Cmax and AUC0–72, with subjects within the series as a random effect and period, series, and formula as fixed effects. The Mann-Whitney U test was used to compare the PK profile between the fasting and fed groups. SPSS (version 22.0) was used to conduct statistical analysis. The ratios of geometric least square mean and the corresponding 90% confidence intervals (CI) of the Cmax and AUC0–72 were computed, and bioequivalence was demonstrated between the test and reference formulations if the 90% CI of Cmax and AUC0–72 fell within the predetermined range 80.00–125.00%. A nonparametric test was applied to analyze Tmax. Statistical analyses were carried out using SAS version 9.4 (SAS Institute, Inc., Cary, North Carolina), and p-values of <0.05 were considered statistically significant.

Safety Assessment

A safety assessment was conducted by vital sign measurements, physical examinations, electrocardiograms, and laboratory tests at baseline, at the indicated time points following drug administration, and the next day after study completion. Every adverse event was recorded.

Result

Demographic Characteristics

In total, 64 healthy subjects participated in the study: 32 for the fasting and fed cohorts. Of the 63 subjects who completed the study, one subject withdrew from the fed cohort. Detailed demographic information about all patients is presented in Table 1.

Table 1

Demographic characteristics of subjects

DemographicsFasting (n = 32)Fed (n = 32)
Male/female, n24/824/8
Age, y26.0 ± 5.824.9 ± 6.1
Height, cm168 ± 8.0167 ± 7.0
Weight, kg62.4 ± 7.862.9 ± 7.6
BMI, kg/m221.8 ± 1.622.3 ± 1.8

BE Studies and Effect of Food on PK

The mean serum concentration-time curves of two formulations of linagliptin products, each administered as a single 5 mg oral dose to 64 healthy Chinese volunteers, are shown in Figure 2. Table 2 shows the values of the primary PK parameters for linagliptin following administration under fasting or fed conditions. There were no significant differences between the test drug and the reference drug, whether in the fasting or the fed group. As to the effect of food on the PK, we found the concurrent intake of food increased the time to reach maximum plasma concentration by approximately 1 hour and decreased Cmax by about 30%, the AUC0–72 in the fed condition was also decreased compared to the fasting condition. The results from the Mann-Whitney U test (Table 3) indicated that Changes among Cmax (p < 0.05) and AUC0–72 (p < 0.05) were statistically significant in test drug and reference drug when comparing fed condition with fasting condition, Tmax was increased in the fed state, but not statistically significant. As shown in Table 4, the 90% CIs for the ratio (test/reference) of log-transformed Cmax and AUC0–72 were 95.9–110.9% and 96.8–101.9% in the fasting group, and 98.2–103.4% and 97.7–103.5% in the fed group, respectively. These were within the acceptance range of 80–125%, indicating that the test preparation was equivalent to the reference preparation in healthy Chinese subjects under both the fasting and fed conditions.

Mean (±SEM) plasma concentration-time curves (a) and semilogarithmic curves (b) of the test and the reference products of Linagliptin in healthy subjects under fasting conditions.
Fig. 2  Mean (±SEM) plasma concentration-time curves (a) and semilogarithmic curves (b) of the test and the reference products of Linagliptin in healthy subjects under fasting conditions.

Mean (±SEM) plasma concentration-time curves (c) and semilogarithmic curves (d) of the test and the reference products of Linagliptin in healthy subjects under fed conditions.

Table 2

Bioavailability parameters of the test and reference formulations under fasting and fed conditions

ParameterFasting
Fed
Test (n = 32)Reference (n = 32)Test (n = 32)Reference (n = 31)a
Tmax (h)1.9 (0.5, 8.0)1.5 (0.5, 12.0)2.0 (0.8, 24.0)3.0 (0.8, 4.5)
Cmax (ng/mL)5.5 ± 2. 65.2 ± 2.13.5 ± 0.73.5 ± 0.6
AUC0–72 (h*ng/mL)159.3 ± 25.2160.9 ± 27. 7145.1 ± 28.0144.9 ± 28.7
Table 3

Effects of food on the PK parameters of linagliptin

ParameterMann-Whitney U test
TestReference
Tmax (h)0.8310.069
Cmax (ng/mL)<0.01*<0.01*
AUC0–72 (h*ng/mL)0.003*0.01*
Table 4

Bioequivalence between the Test (T) and Reference (R) linagliptin tablets in healthy Chinese subjects under fasting and fed conditions

ParameterFasting
Fed
(T/R) GMR90% CI (%)Intraindividual Variability (%)power(T/R) GMR90% CI (%)Intraindividual Variability (%)power
Cmax (ng/mL)103.195.9–110.917.399.5100.798.2–103.45.8100.0
AUC0–72 (h*ng/mL)99.396.8–101.96.1100.0100.597.7–103.56.5100.0

Safety Assessment

From Table 5, there were six AEs (Adverse Events) reported in four (6.3%) of 64 subjects in the fasting group. These AEs were mild (Grade I) and thought to be associated with the administration of the drug. Especially five AEs occurred in the test drug period, whereas one AE was reported in the reference drug period. Finally, one AE was improved when five AEs had completely recovered at the last scheduled visit.

Table 5

Adverse events of subjects after study drug

AEs, n (%)Fasting
Fed
All (N = 64)
Test (n = 32)Reference (n = 32)Test (n = 32)Reference (n = 31)a
All AEs3 (9.4%)1 (3.1%)3 (9.4%)2 (6.5%)9 (14.1%)
Leukocytosis1 (3.1%)001 (3.1%)2 (3.1%)
Elevated platelet1 (3.1%)0001 (1.6%)
Prolonged thrombin time001 (3.1%)01 (1.6%)
Increased triglycerides01 (3.1%)3 (9.4%)04 (6.3%)
Elevated Serum creatine phosphokinase0001 (3.1%)1 (1.6%)
Anemia1 (3.1%)0001 (1.6%)
Dizzy1 (3.1%)0001 (1.6%)
Weak1 (3.1%)0001 (1.6%)

Also, six AEs (Adverse Events) were reported in five (7.9%) of 63 subjects in the fed group. These AEs were mild (Grade I) and thought to be associated with the administration of the drug. Among these, three AEs occurred in the test drug period, whereas in the reference drug period, two AE was reported. Finally, three AEs completely recovered at the last scheduled visit. No serious adverse events occurred in the fasting or the fed cohorts, nor were any AEs leading to withdrawal. There was no statistically significant difference between the test and reference products in the incidence of adverse events.

No severe AEs or AEs were leading to withdrawal in the fasting and fed cohorts. The difference in the incidence of AEs between the test and reference products was not statistically significant.

Discussion

The bioequivalence of generic linagliptin to the branded tablet in healthy Chinese subjects was established on fasting and fed Chinese subjects through the two-period, crossover, phase I study. Of course, the 5 mg dose was safe and well tolerated, consistent with previous clinical studies.35,36 No adverse events or clinically significant changes in the study were reported.

Compared with some of the standard therapies for DM2, DPP4 inhibitors showed fewer limitations.37 Compared with other DPP4 inhibitors, linagliptin showed more obvious advantages. Firstly, linagliptin is considered safe in renal failure.38 Linagliptin undergoes enterohepatic cycling and is excreted primarily (85%) in the bile, while the elimination of other DPP-4 inhibitors is performed mainly through renal excretion, with 60∼85% of each dose eliminated as an unchanged parent compound in the urine.39 Secondly, as a weak competitive inhibitor of CYP3A4, linagliptin just resulted in a little decrease in the clearance of other drugs metabolized by CYP3A4. As a substrate for CYP3A4, linagliptin has a similar exposure regardless of whether CYP3A4 inhibition or induction is present. Thus, linagliptin is considered to have a low potential for clinically relevant interactions. Moreover, a study40 suggested that compared with other DPP-4 inhibitors, linagliptin possessed the best overall balance between potency and the clinical pharmacokinetic characteristics of distribution, metabolism, and elimination.

With a high-fat meal, we observed that the Tmax of linagliptin was delayed about 1 h, and Cmax was decreased by about 30% in the study. Meanwhile, linagliptin concentrations in plasma were slightly higher in a fed condition beyond 12 hours after dosing. Food-induced increase in AUC0–72h was consistent with the observation in Graefe-Mody U’s study.41 Food delayed the absorption rate of linagliptin but did not affect the extent of absorption. Food was involved in drug absorption and distribution via various mechanisms, including a direct drug-food interaction or a change in physiological conditions. Considering linagliptin is a substrate for CYP3A4, food may affect the absorption rate by regulating the activity of CYP3A4. Also, the solubility of the drug in vivo was different in fasting and fed conditions,42 food increased viscosity of the stomach contents and slowed down gastric emptying rate, which may be the reason for the decreased Cmax and prolonged Tmax of linagliptin in the fed group.

Considering the presentation of DM2 was different between patients of Asian and Caucasian origin,4346 whether these differences based on ethnicity affect the PK characteristics of linagliptin? From a review published in 2017,37 we acknowledged that small changes in PK parameters were observed when linagliptin was given to Caucasian, Japanese, and Chinese patients, but this is not considered clinically relevant.

Further directions

Of course, the study also existed a shortcoming. Blood DPP-4 levels could be measured to assess trends in DPP-4 levels over time before and after drug administration. Therefore, we could evaluate the influence of drugs on DPP-4 levels in vivo by determining the DPP-4 level in the blood samples of each subject. Meanwhile, we could evaluate linagliptin’s action mode and characteristics in vivo more comprehensively by combining them with the PK results.

Conclusions

In the study, two formulations were well-tolerated in healthy Chinese volunteers. All AEs were mild. Linagliptin showed a clean safety profile in this study with an AE rate similar to that of the placebo of the reference drug. Our data recommended that the generic linagliptin capsule is safe and may be a cost-effective alternative to the branded linagliptin for DM2 patients in China, especially with kidney insufficiency.

Abbreviations

AEs: 

adverse events

AUC: 

area under the plasma concentration-time curve

AUC0-72

AUC from zero to time 72h

CI: 

confidence intervals

Cmax

maximum plasma drug concentration

DM: 

diabetes mellitus

DM2: 

type 2 diabetes mellitus

DPP4: 

dipeptidyl deptidase-4

GLP-1: 

glucagon-like Peptide-1

GIP: 

glucose-dependent insulinotropic peptide

IR: 

insulin resistance

PK: 

pharmacokinetics

QC: 

quality control

SAS: 

statistical analysis system

Tmax

time to reach maximum plasma concentration

Declarations

Acknowledgement

We sincerely thank all the volunteers for participating in this clinical study.

Ethical statement

The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All procedures in the study involving human participants were in accordance with the ethical standards of the institutional and/or national research committee(s) and with the Declaration of Helsinki (as revised in 2013). Written informed consent was obtained from the patient.

Data sharing statement

No additional data are available.

Funding

None.

Conflict of interest

XL has been an editorial board member of the Journal of Exploratory Research in Pharmacology since January 2020. KY is the project manager of Brilliant Pharmaceuticals Co., Ltd. The authors have no other conflicts of interest to declare.

Authors’ contributions

All the authors contributed substantially to the manuscript. XL participated in the study concept and design; XL contributed to assay performance and data analysis; XL and KY performed the administration; XL and FY designed the study; FY contributed to manuscript writing; XL contributed to the critical revision of the manuscript.

References

  1. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005;365(9467):1333-1346 View Article PubMed/NCBI
  2. Multhaup ML, Seldin MM, Jaffe AE, Lei X, Kirchner H, Mondal P, et al. Mouse-human experimental epigenetic analysis unmasks dietary targets and genetic liability for diabetic phenotypes. Cell Metab 2015;21(1):138-149 View Article PubMed/NCBI
  3. Farmer A, Fox R. Diagnosis, classification, and treatment of diabetes. BMJ 2011;342:d3319 View Article PubMed/NCBI
  4. Gudmundsdottir V, Pedersen HK, Mazzoni G, Allin KH, Artati A, Beulens JW, et al. Whole blood co-expression modules associate with metabolic traits and type 2 diabetes: an IMI-DIRECT study. Genome Med 2020;12(1):109 View Article PubMed/NCBI
  5. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract 2019;157:107843 View Article PubMed/NCBI
  6. Mentlein R. Mechanisms underlying the rapid degradation and elimination of the incretin hormones GLP-1 and GIP. Best Pract Res Clin Endocrinol Metab 2009;23(4):443-452 View Article PubMed/NCBI
  7. Deacon CF. Circulation and degradation of GIP and GLP-1. Horm Metab Res 2004;36(11-12):761-765 View Article PubMed/NCBI
  8. Sim AY, Barua S, Kim JY, Lee YH, Lee JE. Role of DPP-4 and SGLT2 Inhibitors Connected to Alzheimer Disease in Type 2 Diabetes Mellitus. Front Neurosci 2021;15:708547 View Article PubMed/NCBI
  9. Uto A, Miyashita K, Endo S, Sato M, Ryuzaki M, Kinouchi K, et al. Transient Dexamethasone Loading Induces Prolonged Hyperglycemia in Male Mice With Histone Acetylation in Dpp-4 Promoter. Endocrinology 2021;162(12):bqab193 View Article PubMed/NCBI
  10. Czogała W, Czogała M, Kwiecińska K, Bik-Multanowski M, Tomasik P, Hałubiec P, et al. The Expression of Genes Related to Lipid Metabolism and Metabolic Disorders in Children before and after Hematopoietic Stem Cell Transplantation-A Prospective Observational Study. Cancers (Basel) 2021;13(14):3614 View Article PubMed/NCBI
  11. Lin CP, Huang PH, Chen CY, Wu MY, Chen JS, Chen JW, et al. Sitagliptin attenuates arterial calcification by downregulating oxidative stress-induced receptor for advanced glycation end products in LDLR knockout mice. Sci Rep 2021;11(1):17851 View Article PubMed/NCBI
  12. Lamers D, Famulla S, Wronkowitz N, Hartwig S, Lehr S, Ouwens DM, et al. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes 2011;60(7):1917-1925 View Article PubMed/NCBI
  13. Sell H, Blüher M, Klöting N, Schlich R, Willems M, Ruppe F, et al. Adipose dipeptidyl peptidase-4 and obesity: correlation with insulin resistance and depot-specific release from adipose tissue in vivo and in vitro. Diabetes Care 2013;36(12):4083-4090 View Article PubMed/NCBI
  14. Zheng T, Chen T, Liu Y, Gao Y, Tian H. Increased plasma DPP4 activity predicts new-onset hypertension in Chinese over a 4-year period: possible associations with inflammation and oxidative stress. J Hum Hypertens 2015;29(7):424-429 View Article PubMed/NCBI
  15. Ghorpade DS, Ozcan L, Zheng Z, Nicoloro SM, Shen Y, Chen E, et al. Hepatocyte-secreted DPP4 in obesity promotes adipose inflammation and insulin resistance. Nature 2018;555(7698):673-677 View Article PubMed/NCBI
  16. Zheng TP, Yang F, Gao Y, Baskota A, Chen T, Tian HM, et al. Increased plasma DPP4 activities predict new-onset atherosclerosis in association with its proinflammatory effects in Chinese over a four year period: A prospective study. Atherosclerosis 2014;235(2):619-624 View Article PubMed/NCBI
  17. Zheng T, Baskota A, Gao Y, Chen T, Tian H, Yang F. Increased plasma DPP4 activities predict new-onset hyperglycemia in Chinese over a four-year period: possible associations with inflammation. Metabolism 2015;64(4):498-505 View Article PubMed/NCBI
  18. Carl-McGrath S, Lendeckel U, Ebert M, Röcken C. Ectopeptidases in tumour biology: a review. Histol Histopathol 2006;21(12):1339-1353 View Article PubMed/NCBI
  19. Deacon CF. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2020;16(11):642-653 View Article PubMed/NCBI
  20. Gallwitz B, Rosenstock J, Rauch T, Bhattacharya S, Patel S, von Eynatten M, et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet 2012;380(9840):475-483 View Article PubMed/NCBI
  21. Perkovic V, Toto R, Cooper ME, Mann JFE, Rosenstock J, McGuire DK, et al. Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial. Diabetes Care 2020;43(8):1803-1812 View Article PubMed/NCBI
  22. Sneha P, Doss CG. Gliptins in managing diabetes - Reviewing computational strategy. Life Sci 2016;166:108-120 View Article PubMed/NCBI
  23. Deacon CF, Lebovitz HE. Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas. Diabetes Obes Metab 2016;18(4):333-347 View Article PubMed/NCBI
  24. Fuchs H, Tillement JP, Urien S, Greischel A, Roth W. Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans. J Pharm Pharmacol 2009;61(1):55-62 View Article PubMed/NCBI
  25. Graefe-Mody U, Retlich S, Friedrich C. Clinical pharmacokinetics and pharmacodynamics of linagliptin. Clin Pharmacokinet 2012;51(7):411-427 View Article PubMed/NCBI
  26. Kalra S, Unnikrishnan AG, Agrawal N, Singh AK. Linagliptin and newer DPP-4 inhibitors: newer uses and newer indications. Recent Pat Endocr Metab Immune Drug Discov 2011;5(3):197-202 View Article PubMed/NCBI
  27. Deeks ED. Linagliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs 2012;72(13):1793-1824 View Article PubMed/NCBI
  28. Hüttner S, Graefe-Mody EU, Withopf B, Ring A, Dugi KA. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers. J Clin Pharmacol 2008;48(10):1171-1178 View Article PubMed/NCBI
  29. Yki-Järvinen H, Rosenstock J, Durán-Garcia S, Pinnetti S, Bhattacharya S, Thiemann S, et al. Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a ≥52-week randomized, double-blind study. Diabetes Care 2013;36(12):3875-3881 View Article PubMed/NCBI
  30. Vaculikova E, Placha D, Pisarcik M, Peikertova P, Dedkova K, Devinsky F, et al. Preparation of risedronate nanoparticles by solvent evaporation technique. Molecules 2014;19(11):17848-17861 View Article PubMed/NCBI
  31. Shono Y, Jantratid E, Janssen N, Kesisoglou F, Mao Y, Vertzoni M, et al. Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling. Eur J Pharm Biopharm 2009;73(1):107-114 View Article PubMed/NCBI
  32. Abuhelwa AY, Williams DB, Upton RN, Foster DJ. Food, gastrointestinal pH, and models of oral drug absorption. Eur J Pharm Biopharm 2017;112:234-248 View Article PubMed/NCBI
  33. Baxevanis F, Kuiper J, Fotaki N. Fed-state gastric media and drug analysis techniques: Current status and points to consider. Eur J Pharm Biopharm 2016;107:234-248 View Article PubMed/NCBI
  34. Won CS, Oberlies NH, Paine MF. Mechanisms underlying food-drug interactions: inhibition of intestinal metabolism and transport. Pharmacol Ther 2012;136(2):186-201 View Article PubMed/NCBI
  35. Friedrich C, Shi X, Zeng P, Ring A, Woerle HJ, Patel S. Pharmacokinetics of single and multiple oral doses of 5 mg linagliptin in healthy Chinese volunteers. Int J Clin Pharmacol Ther 2012;50(12):889-895 View Article PubMed/NCBI
  36. Sarashina A, Sesoko S, Nakashima M, Hayashi N, Taniguchi A, Horie Y, et al. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects. Clin Ther 2010;32(6):1188-1204 View Article PubMed/NCBI
  37. Ceriello A, Inagaki N. Pharmacokinetic and pharmacodynamic evaluation of linagliptin for the treatment of type 2 diabetes mellitus, with consideration of Asian patient populations. J Diabetes Investig 2017;8(1):19-28 View Article PubMed/NCBI
  38. Guedes EP, Hohl A, de Melo TG, Lauand F. Linagliptin: farmacology, efficacy and safety in type 2 diabetes treatment. Diabetol Metab Syndr 2013;5(1):25 View Article PubMed/NCBI
  39. Russo E, Penno G, Del Prato S. Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin. Diabetes Metab Syndr Obes 2013;6:161-170 View Article PubMed/NCBI
  40. Golightly LK, Drayna CC, McDermott MT. Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. Clin Pharmacokinet 2012;51(8):501-514 View Article PubMed/NCBI
  41. Graefe-Mody U, Giessmann T, Ring A, Iovino M, Woerle HJ. A randomized, open-label, crossover study evaluating the effect of food on the relative bioavailability of linagliptin in healthy subjects. Clin Ther 2011;33(8):1096-1103 View Article PubMed/NCBI
  42. Zhang H, Xia B, Sheng J, Heimbach T, Lin TH, He H, et al. Application of physiologically based absorption modeling to formulation development of a low solubility, low permeability weak base: mechanistic investigation of food effect. AAPS PharmSciTech 2014;15(2):400-406 View Article PubMed/NCBI
  43. Chan JC, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon KH, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 2009;301(20):2129-2140 View Article PubMed/NCBI
  44. Ramachandran A, Snehalatha C, Vijay V. Low risk threshold for acquired diabetogenic factors in Asian Indians. Diabetes Res Clin Pract 2004;65(3):189-195 View Article PubMed/NCBI
  45. Ma RC, Chan JC. Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States. Ann N Y Acad Sci 2013;1281:64-91 View Article PubMed/NCBI
  46. Takeuchi M, Okamoto K, Takagi T, Ishii H. Ethnic difference in inter-East Asian subjects with normal glucose tolerance and impaired glucose regulation: a systematic review and meta-analysis focusing on fasting serum insulin. Diabetes Res Clin Pract 2008;82(3):383-390 View Article PubMed/NCBI
  • Journal of Exploratory Research in Pharmacology
  • eISSN 2572-5505

Bioequivalence Studies of Two Brands of Linagliptin Tablets in Healthy Adults Under Fed and Fasted Conditions

Xin Li, Fang Yuan, Bing Xu, Ke Yao, Gui-Ying Xiao, Yuan Li, Ping Zhang, Sheng-Qing Tu
  • Reset Zoom
  • Download TIFF